LONDON, UK / ACCESSWIRE / July 28, 2016 / Active Wall St. announces the list of stocks for today’s coverage. Pre-market the Active Wall St. team provides the technical notes impacting selected stocks trading on the Toronto Exchange and belonging under the Independent Oil & Gas industry. Companies recently under review include Kelt Exploration, Spartan Energy Corp., Painted Pony Petroleum, and Raging River Exploration. Get all of our research notes free by signing up at: http://www.activewallst.com/register/.

On Wednesday, July 27, 2016, the TSX Composite Index edged 0.02% lower, to finish at 14,546.54. At the close yesterday, the energy index was down 1.58%, finishing at 249.06.

Active Wall St. has initiated coverage on the following equities: Kelt Exploration Ltd (TSX: KEL), Spartan Energy Corporation (TSX: SPE), Painted Pony Petroleum Ltd (TSX: PPY), and Raging River Exploration Inc. (TSX: RRX). Register with us now for your free membership and more at: http://www.activewallst.com/register/.

Kelt Exploration Ltd. (TSX: KEL)

Calgary, Canada headquartered oil and gas company, Kelt Exploration Ltd.’s stock finished Wednesday’s session 1.83% lower at $4.30 with a total volume of 416,574 shares traded. Over the last one month, Kelt Exploration’s shares have lost 2.93%. Shares of the Company, which engages in the exploration, development, and production of crude oil and natural gas resources primarily in west central Alberta and northeastern British Columbia, Canada, are trading above its 200-day moving average. Kelt Exploration’s 50-day moving average of $4.74 is above its 200-day moving average of $4.14. See our notes on KEL.TO at: http://www.activewallst.com/registration-3/?symbol=KEL.

Spartan Energy Corp. (TSX: SPE)

Calgary, Canada headquartered Spartan Energy Corp.’s stock fell 2.14%, to close the day at $3.20. The stock recorded a trading volume of 725,513 shares. Spartan Energy’s shares have advanced 2.56% in the last one month and 9.59% in the past three months. Furthermore, the stock has gained 25.98% in the previous one year. Shares of the company, which operates as an oil and natural gas exploration and production company in Canada and the U.S., are trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $3.31 is greater than its 200-day moving average of $2.86. The complimentary notes on SPE.TO at: http://www.activewallst.com/registration-3/?symbol=SPE.

Painted Pony Petroleum Ltd. (TSX: PPY)

On Wednesday, shares in Painted Pony Petroleum Ltd ended the session 2.10% lower at $7.91 with a total volume of 541,507 shares traded. Shares of Painted Pony Petroleum, which explores for, develops, and produces petroleum and natural gas resources in western Canada, have gained 3.81% in the last one month, 34.98% in the previous three months, and 15.64% in the past one year. The stock is trading above its 50-day and 200-day moving averages. The company’s 50-day moving average of $7.79 is greater than its 200-day moving average of $5.55. Register for free and access the latest notes on PPY.TO at: http://www.activewallst.com/registration-3/?symbol=PPY.

Raging River Exploration Inc. (TSX: RRX)

On Wednesday, shares in junior oil and gas production Calgary, Canada headquartered company, Raging River Exploration Inc. recorded a trading volume of 888,414 shares, which was higher than their three months average volume of 808,919 shares. The stock ended the day 1.18% higher at $10.29. Raging River Exploration’s stock has advanced 1.98% in the last one month and 3.63% in the previous three months. Furthermore, the stock has surged 36.11% in the past one year. The Company is trading above its 200-day moving average. The stock’s 50-day moving average of $10.41 is above its 200-day moving average of $9.70. Shares of the Company, which engages in the exploration, development, and production of crude oil and natural gas properties in Western Canada, traded at a PE ratio of 103.94. Get free access to your notes on RRX.TO at: http://www.activewallst.com/registration-3/?symbol=RRX.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 442942

LONDON, UK / ACCESSWIRE / July 28, 2016 / Active Wall St. announces the list of stocks for today’s coverage. Pre-market the Active Wall St. team provides the technical notes impacting selected stocks trading on the Toronto Exchange and belonging under the Gold industry. Companies recently under review include Franco-Nevada, New Gold, Detour Gold, and Alamos Gold. Get all of our research notes free by signing up at: http://www.activewallst.com/register/.

On Wednesday, July 27, 2016, the TSX Composite Index edged 0.02% lower, to finish at 14,546.54. The metals and mining index was up 0.40%, ending the session at 653.60.

Active Wall St. has initiated coverage on the following equities: Franco-Nevada Corporation (TSX: FNV), New Gold Inc. (TSX: NGD), Detour Gold Corporation (TSX: DGC), and Alamos Gold Inc. (TSX: AGI). Register with us now for your free membership and more at: http://www.activewallst.com/register/.

Franco-Nevada Corporation (TSX: FNV)

On Wednesday, shares in Toronto, Canada headquartered Franco-Nevada Corporation ended the session 2.84% higher at $99.18 with a total volume of 395,126 shares traded. Franco-Nevada’s shares have advanced 4.53% in the last one month and 15.23% in the previous three months. Furthermore, the stock has rallied 87.24% in the past one year. The stock is trading above its 50-day and 200-day moving averages. The company’s 50-day moving average of $95.04 is greater than its 200-day moving average of $83.04. Shares in Franco-Nevada, which operates as a gold-focused royalty and stream company in the United States, Canada, Mexico, Peru, Chile, and Africa, traded at a PE ratio of 446.76. See our notes on FNV.TO at: http://www.activewallst.com/registration-3/?symbol=FNV.

New Gold Inc. (TSX: NGD)

Vancouver, Canada-based gold mining company, New Gold Inc.’s stock finished Wednesday’s session 7.89% higher at $6.29 with a total volume of 2.63 million shares traded. Over the last one month and the previous three months, New Gold Inc.’s shares have gained 12.32% and 11.92%, respectively. Furthermore, the stock has surged 116.90% in the past one year. Shares of the Company, which engages in the acquisition, exploration, development, and operation of mineral properties, are trading above its 50-day and 200-day moving averages. New Gold’s 50-day moving average of $5.70 is above its 200-day moving average of $4.95. The complimentary notes on NGD.TO at: http://www.activewallst.com/registration-3/?symbol=NGD.

Detour Gold Corporation (TSX: DGC)

Toronto, Canada headquartered intermediate gold mining company, Detour Gold Corporation’s stock advanced 5.60%, to close the day at $33.18. The stock recorded a trading volume of 1.08 million shares, which was above its three months average volume of 1.05 million shares. Detour Gold Corporation’s shares have gained 0.94% in the last one month and 32.93% in the past three months. Furthermore, the stock has rallied 188.02% in the previous one year. Shares of the company, which engages in the acquisition, exploration, development, and operation of mineral properties in Canada, are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $31.96 is greater than its 200-day moving average of $24.74. Register for free and access the latest notes on DGC.TO at: http://www.activewallst.com/registration-3/?symbol=DGC.

Alamos Gold Inc. (TSX: AGI)

On Wednesday, shares in Toronto, Canada headquartered Alamos Gold Inc. recorded a trading volume of 930,225 shares, which was lower than their three months average volume of 1.03 million shares. The stock ended the day 4.17% higher at $12.00. Alamos Gold’s stock has surged 12.68% in the last one month and 42.18% in the previous three months. Furthermore, the stock has rallied 183.02% in the past one year. Shares of the Company, which explores for, mines, develops, and produces gold deposits in the U.S. and Canada, are trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $11.17 is above its 200-day moving average of $7.92. Get free access to your notes on AGI.TO at: http://www.activewallst.com/registration-3/?symbol=AGI.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 442948

LITTLE ROCK, AR / ACCESSWIRE / July 28, 2016 / Inuvo, Inc. (NYSE MKT: INUV), an advertising technology and digital publishing company, today announced the Company will release its 2016 second quarter financial results on Thursday, August 4, 2016. Mr. Richard Howe, President and Chief Executive Officer, and Mr. Wally Ruiz, Chief Financial Officer, will host a conference call the same day at 4:30 p.m. (ET).

Conference Call Information:

Date: Thursday, August 4, 2016
Time: 4:30 p.m. ET
Domestic Dial-in number: 1-877-723-9520
International Dial-in number: 1-719-325-4762
Live webcast: http://public.viavid.com/index.php?id=120590

A telephone replay will be available through August 18, 2016. To access the replay, please dial 1-877-870-5176 (domestic) or 1-858-384-5517 (international). At the system prompt, enter the code 7777724 followed by the # sign. You will then be prompted for your name, company and phone number. Playback will then automatically begin.

About Inuvo, Inc.

Inuvo®, Inc. (NYSE MKT: INUV) is an advertising technology and digital publishing business that serves millions of income generating ads monthly across a network of websites and apps serving desktop, tablet and mobile devices. To learn more about Inuvo, please visit www.inuvo.com or download our app for Apple iPhone or for Android.

Company Contact:


Inuvo, Inc.
Wally Ruiz, Chief Financial Officer
501-205-8397
Wallace.Ruiz@Inuvo.com

or

Investor Contact:

Capital Markets Group, LLC
PH: 914-669-0222
Info@CapMarketsGroup.com
www.CapMarketsGroup.com

SOURCE: Inuvo, Inc.

ReleaseID: 442870

LAS VEGAS, NV / ACCESSWIRE / July 28, 2016 / The Biotechnology sector is still struggling with a personal bear market, after dropping 40% from its high point in July 2015. While the overall market has strengthened and risen quite a bit from its lows, the biotechnology sector, as represented by IBB, an ETF tracking the Nasdaq Biotechnology Index, is still down 24% for the year. While the broader indexes have enjoyed some resurgence, the IBB has not been able to even come close to the 200 DMA level this year, and was 11% below it at the end of June.

One major thing that has held back the sector has been the political rhetoric of an election year around managing drug prices. While the political issue of rising health care costs and aggressive pricing practices will remain prominent throughout the year, as Presidential candidates posture and Congress conducts more hearings, last month it seemed that the other concerns were dissipating.

That was before the Brexit gripped the market during June. Biotechnology along with the broader market, pulled back on concerns of a British Exit. The key difference between the biotech and the broader market pullback was that the IBB returned back exactly to its yearly low of 240, a level touched in February 2016, while all the key indexes representing the broader market stabilized much higher than their yearly lows. Interestingly, the IBB index bounced back with the broader market and by the close of day on July 1, had returned to its pre-Brexit level.

We believe that conditions which existed prior to Brexit, and made us look forward towards a stronger performance from the Biotech sector, continue to exist and should benefit the biotechs going forward.

Here’s a few biotechs to consider riding the impending resurgence with:

Endonovo Therapeutics, Inc. (ENDV), a developer of bioelectronic devices and medicines, announced recently that it had entered into a binding letter of intent to acquire fellow bioelectronics/electroceuticals developer Rio Grande Neurosciences, Inc. for an aggregate purchase price of $21.5 million. ENDV has already paid Rio Grande Neurosciences $500,000 towards the purchase price through the issuance of a note. The LOI is binding and only subject to the execution of a definitive purchase agreement and shareholder approvals.

The acquisition firmly establishes ENDV as a leader in neuromodulation and bioelectronic medicine, as the transaction brings an FDA-cleared electroceutical device for treating post-operative pain and edema and a pending FDA 510(k) multi-coil repetitive Transcranial Magnetic Stimulation (rTMS) device for treating resistant major depressive disorder.

Furthermore, the transaction adds to ENDV’s overall mission to reduce inflammation in vital organs. Rio Grande’s FDA-Cleared Electroceutical is entering clinical trials for multiple neuroinflammatory and central nervous system disorders and conditions, such as Traumatic Brain Injury (TBI) for which there are currently no effective treatments, acute concussion, post-concussion syndrome, and multiple sclerosis.

With this announced acquisition flying under the radar, investors are excited to get involved with ENDV and it’s easy to see why.

Recently, the company received a price target of $1.15 from See Thru Equity research. With the company currently priced at 21 cents a share, reaching the target price would represent a 448% price gain.

Eleven Biotherapeutics, Inc. (EBIO) announced Friday that an investigational new drug application for diabetic macular edema drug EBI031 has become effective. As a result of this milestone, Eleven is entitled to receive a $22.5 million payment from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) pursuant to the terms of its license agreement with Roche.

Anthera Pharmaceuticals, Inc. (ANTH) was assigned an average rating of “Buy” from the seven research firms that are currently covering the stock.

Anavex Life Sciences, Corp. (AVXL) is a clinical stage biopharmaceutical company which is focusing on the development of drugs/therapies for the treatment of neurodegenerative and neuro-developmental diseases. The company just presented data from its Phase 2a study of its lead candidate, ANAVEX 2-73, in Alzheimer’s patients at the Alzheimer’s Association International Conference® (AAIC) 2016. Overall, the results show what appears to be a converging and consistent response for all quantitative endpoints through 31 weeks.

Regulus Therapeutics, Inc. (RGLS) suffered a setback with the company receiving a verbal notice from the FDA placing its IND for experimental HCV treatment, RG101, on clinical hold. The clinical hold was placed after the company reported a second serious adverse event (SAE) of jaundice in an early stage study. The news led to a 49.3% decline in the company’s stock price. However, the shares seem to be oversold as the stock has began to make a strong comeback.

XOMA Corporation (XOMA) a leader in the discovery and development of therapeutic antibodies, recently announced it has initiated its Phase 2 proof of concept study for XOMA 213. XOMA 213 (formerly referred to as LFA102) is a monoclonal antibody that neutralizes prolactin induced signaling. Prolactin is a protein that in normal postpartum females enables the production of milk. In some cases, including prolactinomas, which are benign tumors of the pituitary gland in both men and women, excess secretion can lead to various clinically significant abnormal signs and symptoms.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

SOURCE: ACR Communication, LLC

ReleaseID: 442953

TULSA, OK / ACCESSWIRE / July 28, 2016 / AppSwarm, Inc. (PINKSHEETS: SWRM), is pleased to announce the acquisition of “Avenging Soldiers” from notable mobile games developer Freak X Apps.

Avenging Soldiers is a fast-paced, action combat game designed for smart phones and tablets. Players must battle across 8 exciting levels to discover the 3 hidden keys, shoot the enemies, and stay alive. But you need to be fast – there is a limited time to complete each level. With 4 different characters and 5 weapons to choose from, Avenging Soldiers is sure to keep gamers coming back for more.

Avenging Soldiers is scheduled to be released in the app stores next month, available on iPhone, Android, and tablet. Watch the trailer of Avenging Soldiers here https://goo.gl/L9tVIG and follow us on Facebook (facebook.com/AppSwarm) for the launch date to download and play for free.

“Avenging Soldiers is amazingly fun, fast, and addictive,” says Ron Brewer, AppSwarm’s CEO. “It’s a classic run, jump, shoot platform game, the likes of Mario Bros, Mega Man, and Contra. The team at Freak X did a fantastic job developing quality visuals, precise controls, and physics-based game play. It’s a timeless arcade game theme that is sure to keep gamers of all ages entertained for hours.”

“We are very excited to be working with the AppSwarm team and to be releasing our latest game with them,” said Avenging Soldiers creator Aashish Arora. “We expect this is the start of a great relationship to launch more of our awesome games in the near future. We just love developing simple yet addictive games!”

Freak X Apps published their first app in 2014, and now have a stable of 31 apps available in Google Play. Total Android downloads for Freak X Apps is over 358,000 and the average users’ rating for Freak X Apps is 3.8/5. Freak X Apps develops Action, Adventure, Arcade, Racing, and Sports gaming genre apps.

“We were presented with the opportunity to acquire this action combat platform game and after in-depth due diligence, we decided this was a great opportunity for our company and a new partnership with Freak X,” states Brewer. “Mr. Arora and his team have a deep understanding of classic gaming that is prevalent in the industry right now and ingrained into the folklore of gamers globally. We see this as a first, in a line of products, from our development partner Freak X.”

About AppSwarm

We accelerate the development of mobile games and fast-track them to market. We partner with game developers through joint ventures, royalty agreements, marketing partnerships, and outright purchase through our publically-traded company on the OTC markets, ticker SWRM.

For more information, visit us at www.app-swarm.com, or follow us on Facebook (facebook.com/AppSwarm) or Twitter twitter.com/AppSwarm.

Disclosures

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Contact info

Investor and media contacts call 1-800-706-7656 or email us at info@app-swarm.com.

SOURCE: AppSwarm, Inc.

ReleaseID: 442939

WINNIPEG, MANITOBA / ACCESSWIRE / July 28, 2016 / Gossan Resources Limited (GSS-TSX.V) (GSR-Frankfurt/Freiverkehr & Xetra) has acquired a new property in the zinc-rich polymetallic Sturgeon Lake Greenstone Belt in northwestern Ontario comprised of 15 claims totaling 3,344 hectares. The property is directly along strike and to the east of 6 Volcanogenic Massive Sulfide (VMS) deposits that were mined between 1970 and 1991. Approximately 18.7 million tonnes of ore was mined from these VMS deposits with typical grades of 8.0% zinc, 1.1% copper, 0.8% lead, 120 gpt silver and 0.5 gpt gold.

In November 2015, the Company staked three claims and recently acquired an additional 12 claims from Excalibur Resources Ltd. along with a significant amount of exploration data. Recent work now in the possession of Gossan includes: a VTEM electromagnetic geophysical survey by Geotech Ltd.; an Enzyme Leach geochem survey and a Soil Gas Hydrocarbon geochem survey, both processed by Actlabs; and results from a limited drill program on the eastern portion of the acquired claims. Gossan believes the best geophysical targets have yet to be drill tested. They are located on the west end of the new property and are along strike and closest to the historic Sturgeon Lake ore deposits.

Douglas Reeson, President of Gossan Resources stated: “Gossan acquired the property to explore what it believes are the most prospective untested targets along the historic Sturgeon Lake Camp. Management believes this property has the potential to host significant Zinc-rich VMS polymetallic deposits. Gossan is well positioned to take advantage of the current rise in zinc prices, supported by the abundance of copper and silver in the Sturgeon Lake Camp”.

The most notable former mines in the camp produced from high-grade zinc-copper-silver ores with associated lead and gold. These properties are currently held by Glencore and First Quantum Minerals. The well-known Mattabi, Lyon Lake and Sturgeon Lake mines operated in proximity and along strike just to the west of Gossan’s new property. The grades and tonnages of these former producers are provided in the table below.

Historical Production from Mineral Deposits of the Sturgeon Lake Mining Camp*

 
Grade
DEPOSIT
Zn
(wt.%)
Cu
(wt.%)
Pb
(wt.%)
Ag
(g/t)
Au
(g/t)
Metric
Tonnes
F Group
9.51
0.64
0.64
60.4
–
340,000
Mattabi
8.28
0.74
0.85
104.0
–
11,400,000
Lyon Lake and
SubCreek Zone
6.53
1.24
0.63
141.5
0.5
3,945,000
Creek Zone
8.80
1.66
0.76
141.5
0.5
908,000
Sturgeon Lake
9.17
2.55
1.21
164.2
0.5
2,070,000

* Franklin et al (1995), Geology of Canadian Mineral Deposit Types: GSC

As of March 31, 2016, Gossan had incurred acquisition costs for this property of $12,800.

Hamid Mumin, P.Geo., a Gossan Director is the Company’s Qualified Person and he has reviewed and approved the technical contents of this news release.

Gossan Resources Limited is engaged in mineral exploration and development in Manitoba and northwestern Ontario. It has a well-diversified portfolio of properties hosting gold, platinum group and base metals, as well as the specialty and minor metals, vanadium, titanium, tantalum, lithium and chromium. The Company also has a large deposit of high-purity, magnesium-rich dolomite and various financial interests in a frac sand deposit. The company trades on the TSX Venture and the Frankfurt/Freiverkehr & Xetra Exchanges and currently has 33,170,400 common shares outstanding.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For further information, please bookmark www.gossan.ca or contact:

Douglas Reeson, Chairman & CEO
Gossan Resources Limited
Tel: (416) 533-9664
E-Mail: info@gossan.ca

Kathy Ringland, Office Manager
Tel : (204) 943-1990

SOURCE: Gossan Resources Limited

ReleaseID: 442954

NEW YORK, NY / ACCESSWIRE / July 28, 2016 / Newsweek magazine called NASH “The 21st Century’s Looming Public Health Threat”. Dieting can save people in the early stages, if it’s diagnosed. After that, there’s nothing. A little known yet lethal disease, non-alcoholic steatohepatitis (NASH) is the advanced form of non-alcoholic fatty liver disease (NAFLD) characterized by fat build up in the liver. Rising prevalence and no approved therapy make it an indication aggressively pursued by the pharma industry. Once approved treatments come to market, Deutsche Bank projects their annual sales to be in the $35 – $40 billion range by 2025. While several companies have been pursuing the indication for some years, Can-Fite BioPharma (NYSE MKT: CANF) is jumping into Phase II trials for NASH with its promising liver disease drug candidate CF102.

The beauty of CF102 – it has shown in clinical and preclinical studies to heal and repair numerous key liver functions. Because CF102 is now in a global Phase II study for the treatment of liver cancer, Can-Fite can leverage this into launching its Phase II NASH study in the same countries where it already has clearance to study CF102 in liver cancer.

Diabetes, a recognized epidemic in the U.S. because 29 million people live with the disease, actually pales in comparison to the number of people with NAFLD. An astonishing 67 million people in the U.S. have NAFLD. Anywhere from 5.6 to 8.4 million Americans are living with NASH and .89 to 2.52 million of those will get cirrhosis. In later stages, NASH is known to lead to liver cancer and liver failure.

The public health threat comes in the fact that at current growth rates, there won’t be enough liver donors available to save people needing liver transplant due to NASH. The second largest organ of the body, the liver has an essential role in human health, removing harmful substances from our blood and processing what we eat and drink into energy and nutrients the body can use. NASH is the third leading cause of liver transplants in the U.S. today and is expected to surpass hepatitis C as the leading cause for liver transplants by 2020.

25 million Americans will have NASH by 2025, driven by rising obesity rates. This is huge. To put this into perspective, 3.2 million people in the U.S. have hepatitis C. Based on the dire need, the U.S. FDA is likely to grant Breakthrough and Fast Track Designations to speed up the most promising NASH drugs in development today. The FDA has already granted Breakthrough Therapy Designation for Intercept’s (ICPT) OCA which is in Phase III for NASH.

Can-Fite announced it plans to conduct a 75 patient double blind, placebo controlled, Phase II study at leading medical centers in Israel, following submission of its protocol to review boards at those clinics in the fourth quarter of this year. The study will test CF102’s ability to treat NAFLD using measures including a reduction in liver fat, something CF102 has already proven it can do in preclinical studies.

Other players in the market for NASH include Genfit (GNFTF) for its drug Elafibranor and India-based Zydus Cadila with its drug Lipaglyn, both in U.S. FDA Phase III trials. A handful of other companies are in Phase II. Due to the unmet need and huge market size, a number of other biotechs, and through partnerships, a few big pharma players Sanofi (SNY) and Bristol Myers Squibb (BMY), are angling to advance their NASH drug candidates.

Many different therapies, some used in combination, will likely be needed in the NASH market. Because the causes of NASH are not yet clearly understood, different drugs may be more efficacious in different people. Not all people with NASH are overweight, obese, or have diabetes. The disease is occurring more often than expected in people who have no apparent risk factors.

As an oral tablet, with a superb safety profile, CF102 is a drug candidate to bet on for NASH. Preclinical studies of CF102 have shown efficacy in the treatment of liver regeneration and function following liver surgery. CF102 revealed its capability to improve liver pathology in an animal model of NASH. CF102 also had a statistically significant reduction in NAFLD activity score compared to placebo. Can-Fite’s drug reduced liver-to-body weight compared to placebo and reduced liver fat levels as compared to placebo.

Beyond NASH, CF102 has received Fast Track Designation in the U.S. and Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency in the treatment of liver cancer. Can-Fite has proven its ability to advance forward into Phase III trials. Its lead drug candidate, Piclidenoson, is about to enter Phase III for psoriasis and rheumatoid arthritis. With a portfolio that includes two indications in Phase II and two more in Phase III, all addressing multi-billion markets, at a $30 million market cap, Can-Fite is a bargain.

HC Wainright’s analyst agrees with me. The firm has a buy recommendation on the stock with a price target of $6.00 per share, more than double where it is trading over the past month in the $2.00 – $2.50 range.

RAY DIRKS Research suggests that Readers/Investors place no more than 1% of the funds they devote to common stocks in any one issue. It’s best to diversify.

About Ray Dirks

Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high -net worth investors both in the U.S. and internationally.

In 1973 Ray uncovered the biggest Ponzi scheme of the 20th century, the Equity Funding fraud. Over the years Ray has expanded his stock market research to include Healthcare Stocks and Special Situations. Ray has written two books, “The Great Wall Street Scandal” and “Heads You Win, Tails You Win,” published by McGraw-Hill and Bantam Books respectively. He continues to provide research to institutions and individuals, and he manages money for some individual investors.

Contact:

Jackie Rodriguez
(646)-430-5783

SOURCE: RAY DIRKS Research

ReleaseID: 442940